Where is Cognition Therapeutics headquartered?

COGNITION THERAPEUTICS INC is recorded with headquarters in Purchase, USA in NovaPharmaNews public regulatory and sponsor datasets.

Is Cognition Therapeutics publicly traded?

Yes — Cognition Therapeutics is listed as a public company with ticker CGTX on NYSE in SEC EDGAR-derived records.

What drugs are associated with Cognition Therapeutics?

We link 1 drug profile(s) where Cognition Therapeutics appears as originator or marketer in FDA or regional approval metadata.

What clinical trials is Cognition Therapeutics sponsoring?

Cognition Therapeutics is linked to 33 pipeline program(s) sourced from ClinicalTrials.gov and EU CTIS where sponsor names match.

What patents list Cognition Therapeutics as applicant?

12 USPTO PatentsView record(s) name COGNITION THERAPEUTICS INC or a normalized variant as applicant.

What pipeline phases does Cognition Therapeutics have in our database?

Phase distribution from linked programs: phase 2: 18, phase 1: 4, phase 3: 3.

How many US-approved drugs are linked to Cognition Therapeutics?

1 linked drug profile(s) include US approval status in openFDA-derived metadata.

Where does NovaPharmaNews source data on Cognition Therapeutics?

Profiles combine SEC EDGAR (US issuers), FDA openFDA, EMA medicines data, ClinicalTrials.gov, EU CTIS, USPTO PatentsView, and regional PBS/PMDA/NMPA feeds. See /about/data-sources.

Is Cognition Therapeutics data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

Is Cognition Therapeutics data investment advice?

No. This profile is compiled from public regulatory records for professional reference only, not investment or medical advice.

biotech · Alzheimer Disease · Major Depressive Disorder · CGTX

Cognition Therapeutics

Name: Cognition Therapeutics intelligence dataset
Creator: NovaPharmaNews
License: https://www.sec.gov/edgar.shtml

COGNITION THERAPEUTICS INC

Website Investor relations

2500 Westchester Ave, Purchase, New York 10577, US HQ

2007 Founded

32 Employees

Public company Type

CGTX · NYSE Ticker

Company details

Status: Public
HQ: 2500 Westchester Ave, Purchase, New York 10577, US
Founded: 2007
Employees: 32
Programs: 33
Drugs: 26
Patents: 12

Official website ↗ All projects Drug pipeline Patents News & analysis

Quick answer

Cognition Therapeutics is a biotech organization headquartered in Purchase, USA. It trades on NYSE under ticker CGTX. Primary therapeutic focus areas include Alzheimer Disease, Major Depressive Disorder, Primary biliary cholangitis (PBC), Sleep, Age-Related Macular Degeneration. NovaPharmaNews links 33 clinical program(s), 1 drug profile(s), and 12 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (18), phase 1 (4), phase 3 (3).

Company snapshot

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to helping millions of families seeking effective treatments for devastating neurodegenerative diseases through the development of novel, accessible therapies. The company is advancing its lead candidate, zervimesine (CT1812), for the development of DLB psychosis.

1 approved product(s) across US/EU regulatory metadata.
33 active pipeline program(s) linked via ClinicalTrials.gov.
12 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for Cognition Therapeutics. Not investment advice.

Top assets

View drugs (26) View projects (33)

Lead pipeline drugs

alzheimer
Marketed / approved
anti-
Marketed / approved
benzgalantamine gluconate
approved
butoconazole nitrate
approved

Active clinical programs

CBD 100 mg/mL Oral Solution Treatment Resistant Psychosis
Phase 3
CBD 100 mg/mL Oral Solution Psychosis
Phase 3
Vortioxetine Major Depressive Disorder
Phase 3
Active Comparator CT1812 Age-Related Macular Degeneration
Phase 2

Momentum

Proprietary activity score for Cognition Therapeutics.

1 active signal

20 /100 +0 vs 30 days ago

Signal breakdown

Clinical trials 35 30d
Nova articles 0 30d
Patents filed 0 30d
FDA actions 0 30d
SEC filings 0 30d
Conference presentations 0 90d
Pipeline advances 0 30d

Competitor landscape

Therapeutic-area overlap peers from registry and pipeline signals.

Peer + 0 momentum

vTv Therapeutics

TA overlap score 22.8
Peer + 0 momentum

Neumora Therapeutics

TA overlap score 21
Peer + 0 momentum

Voyager Therapeutics

TA overlap score 20.8

Recent activity

Latest pipeline, patent, and corporate events for Cognition Therapeutics.

Jun 8, 2026 Clinical update
UCAB-CT-05 — Phase 2
Jun 8, 2026 Clinical update
The Modular Protocol for Mental Health — Phase 2
Jun 8, 2026 Clinical update
Oxytocin nasal spray — Phase 2
Jun 8, 2026 Clinical update
Oxytocin nasal spray — Phase 2
Jun 8, 2026 Clinical update
Dexmedetomidine — Phase 2

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

What is Cognition Therapeutics?

Cognition Therapeutics is a biotech organization headquartered in Purchase, USA. It trades on NYSE under ticker CGTX. Primary therapeutic focus areas include Alzheimer Disease, Major Depressive Disorder, Primary biliary cholangitis (PBC), Sleep, Age-Related Macular Degeneration.
Is Cognition Therapeutics publicly traded?

Yes. Cognition Therapeutics is listed with ticker CGTX on NYSE per SEC EDGAR records linked on this profile.
What drugs does Cognition Therapeutics develop or market?

We link 26 drug profile(s) where Cognition Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cognition-therapeutics-inc#company-drugs.
What are the latest developments for Cognition Therapeutics?

In the last 12 months our linked public records show 33 trial program update(s) and 0 US patent grant(s) tied to this profile.
What therapeutic areas does Cognition Therapeutics focus on?

Cognition Therapeutics focuses on Alzheimer Disease, Major Depressive Disorder, Primary biliary cholangitis (PBC) based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others

Neurology

Infectious Disease